416 related articles for article (PubMed ID: 33929089)
1. Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis.
Toyoshima J; Kaibara A; Shibata M; Kaneko Y; Izutsu H; Nishimura T
Pharmacol Res Perspect; 2021 May; 9(3):e00744. PubMed ID: 33929089
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Tanaka Y; Takeuchi T; Tanaka S; Kawakami A; Iwasaki M; Song YW; Chen YH; Wei JC; Lee SH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Akazawa R; Shiomi T; Yamada E
Ann Rheum Dis; 2019 Oct; 78(10):1320-1332. PubMed ID: 31350270
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Iwasaki M; Katayama K; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Shiomi T; Yamada E; van der Heijde D
Ann Rheum Dis; 2019 Oct; 78(10):1305-1319. PubMed ID: 31350269
[TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Song YW; Chen YH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Nakashima Y; Shiomi T; Yamada E
Arthritis Res Ther; 2020 Mar; 22(1):47. PubMed ID: 32164762
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.
Takeuchi T; Tanaka Y; Iwasaki M; Ishikura H; Saeki S; Kaneko Y
Ann Rheum Dis; 2016 Jun; 75(6):1057-64. PubMed ID: 26672064
[TBL] [Abstract][Full Text] [Related]
6. Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
Tanaka Y; Takeuchi T; Izutsu H; Kaneko Y; Kato D; Fukuda M; Rokuda M; Schultz NM
Arthritis Res Ther; 2021 Aug; 23(1):221. PubMed ID: 34429152
[TBL] [Abstract][Full Text] [Related]
7. Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.
Genovese MC; Greenwald M; Codding C; Zubrzycka-Sienkiewicz A; Kivitz AJ; Wang A; Shay K; Wang X; Garg JP; Cardiel MH
Arthritis Rheumatol; 2017 May; 69(5):932-942. PubMed ID: 28118538
[TBL] [Abstract][Full Text] [Related]
8. Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Lee YH; Song GG
Clin Drug Investig; 2020 Jan; 40(1):65-72. PubMed ID: 31602572
[TBL] [Abstract][Full Text] [Related]
9. Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate.
Kivitz AJ; Gutierrez-Ureña SR; Poiley J; Genovese MC; Kristy R; Shay K; Wang X; Garg JP; Zubrzycka-Sienkiewicz A
Arthritis Rheumatol; 2017 Apr; 69(4):709-719. PubMed ID: 27748083
[TBL] [Abstract][Full Text] [Related]
10. Post hoc analysis of patients with rheumatoid arthritis under clinical remission in two Japanese Phase 3 trials of peficitinib treatment (RAJ3 and RAJ4).
Tanaka Y; Takeuchi T; Morita Y; Kato D; Kaneko Y; Terada W
Mod Rheumatol; 2024 Mar; 34(3):453-465. PubMed ID: 37319017
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
12. Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan.
Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Song YW; Chen YH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y
Rheumatol Ther; 2021 Mar; 8(1):425-442. PubMed ID: 33656739
[TBL] [Abstract][Full Text] [Related]
13. Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study.
Blanco FJ; Möricke R; Dokoupilova E; Codding C; Neal J; Andersson M; Rohrer S; Richards H
Arthritis Rheumatol; 2017 Jun; 69(6):1144-1153. PubMed ID: 28217871
[TBL] [Abstract][Full Text] [Related]
14. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
[TBL] [Abstract][Full Text] [Related]
15. Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis.
Levi M; Grange S; Frey N
J Clin Pharmacol; 2013 Feb; 53(2):151-9. PubMed ID: 23436260
[TBL] [Abstract][Full Text] [Related]
16. Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis.
Aletaha D; Maa JF; Chen S; Park SH; Nicholls D; Florentinus S; Furtner D; Smolen JS
Ann Rheum Dis; 2019 Dec; 78(12):1609-1615. PubMed ID: 31434637
[TBL] [Abstract][Full Text] [Related]
17. Investigation of Potential Drug-Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis.
Zhu T; Moy S; Valluri U; Cao Y; Zhang W; Sawamoto T; Chindalore V; Akinlade B
Clin Drug Investig; 2020 Sep; 40(9):827-838. PubMed ID: 32591978
[TBL] [Abstract][Full Text] [Related]
18. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T
JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Int J Rheum Dis; 2020 Jul; 23(7):868-875. PubMed ID: 32483919
[TBL] [Abstract][Full Text] [Related]
20. A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years.
Takeuchi T; Tanaka Y; Rokuda M; Izutsu H; Kaneko Y; Fukuda M; Kato D
Mod Rheumatol; 2021 May; 31(3):543-555. PubMed ID: 33050760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
